Liraglutide restores impaired associative learning in individuals with obesity
But you do not get the full therapeutic benefit
Moreover, dont hesitate to reach out to your healthcare provider for personalized advice and adjustments to your treatment plan
Instead, follow the 'missed dose' guidance in your medication's PIL or contact your healthcare professional
Among new molecules on the horizon for the treatment of overweight and obesity, the most promising appears to be tirzepatide (LY3298176), an incretin mimetic with a dual action targeting both the GLP1 receptor and the glucosedependent insulinotropic polypeptide (GIP) receptor 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 (Figure 2 and Supplementary Figure 1)